Producer
HyTest Ltd.
Finnish biotechnology company (Turku, Finland); specialist manufacturer of diagnostic monoclonal antibodies for cardiac biomarkers; introduced the first anti-cardiac troponin I (cTnI) monoclonal antibodies to market in 1994; supplier to virtually every major cardiac diagnostic test maker (Abbott, Roche, Siemens Healthineers, Beckman Coulter); acquired by Mindray Medical (China's largest medical device company) in 2016 for an undisclosed sum; Mindray ownership means Chinese corporate control of the dominant non-Chinese supplier of troponin I capture antibodies — the gold standard biomarker for myocardial infarction diagnosis
1
Inputs supplied
1
Goods downstream
1
Facilities
1
Stories
What they make
1 input HyTest Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something HyTest Ltd. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Cardiac Biomarker Antibodies
65%Infectious Disease Antibodies
20%Other Diagnostic Components
15%
Stories from the supply chain
Editorial about HyTest Ltd.
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Did you know2024
HyTest Ltd., the Finnish company that supplies troponin I antibodies for most of the world's cardiac emergency diagnostics, was acquired by Mindray Medical International (Shenzhen, China) in 2016. Mindray is China's largest domestic medical device manufacturer and has ties to the Chinese government's strategic healthcare initiatives. This means Chinese corporate ownership controls the antibody supply chain for the cardiac biomarker tests used to diagnose heart attacks in hospitals from New York to London. HyTest continues to operate from Turku under its Finnish brand, but its strategic decisions are made by a Chinese parent.
HyTest Ltd. ↗Origin2023
HyTest Ltd. was founded in Turku, Finland in 1994 to commercialize cardiac troponin antibodies developed from research at Turku University's Department of Biochemistry. The founding team, led by Juhani Astola and colleagues, had made the critical discovery that cardiac troponin I could be measured in blood as a highly specific marker of heart muscle damage -- superior to the previous enzyme-based markers (CK-MB, LDH). HyTest produced the first commercial anti-cTnI monoclonal antibodies and sold them to diagnostic companies including Abbott, Roche, and Siemens Healthineers as the reagent components inside their troponin test kits. The irony: most cardiologists and ER physicians know the Abbott Architect or Roche Elecsys troponin test by brand name, but the antibodies inside these tests -- the component that actually detects the troponin molecule -- come from a small Finnish university spinout most clinicians have never heard of. A Turku biochemistry lab's 1994 discovery became the foundation of the most important test in emergency cardiology globally.
HyTest Ltd. ↗